Ind-Swift Limited - Jawaharpur, Derabassi is the Ace unit of Ind-Swift Limited, was created in the year 2005 with an aim to globalize the Ind-Swift brand for finished dosage forms. We are a 100% Export Oriented Unit dealing in regulated markets having approval like MHRA, TGA & GLC etc.

Ind-Swift Limited are currently seeking qualified candidates for the following positions

Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestina, diabetology, anti-infective and pain management segments. Torrent Pharma has a strong international presence spanning over 70 countries with over 1200 product registrations.

Encube is an integrated pharmaceutical company dedicated only to topical formulations viz. creams, ointments, gels, lotions, and solutions, with 24 years of formidable experience in contract development and manufacturing. Shri Mehul Shah, Promoter and Managing Director, incorporated Encube, on Sep 7, 1995, and commenced commercial operations on Mar 4, 1998.

Syneos Health is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, seamlessly connecting our capabilities to add high-value insights to speed therapies to patients and provide practical value to help our customers achieve their objectives.

Post : Medical Writer II-Narratives

To fill up the vacancies among the sanctioned contractual posts under the National Health Mission as per the Project Implementation Plan as well as the National AYUSH Mission and the Maharashtra State Medical Supplies Procurement Authority apart from the National Civil Health Mission and the National Health Mission  Advertisement of various vacancies in the program at arogya.maharashtra.gov.in It is being published on the website. Following are the general instructions/information regarding the procedure to apply online. 

The origins of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) are rooted in the Indian Cancer Research Centre (ICRC), which was established in 1952 in Parel, Mumbai, under the purview of the Ministry of Health, Government of India.

Assam University came into existence in 1994 after enactment of the Assam (Central) University Act 1989. Through its pursuit, Assam University is in the process of making itself an institute of excellence.  Assam University main campus is situated at Dargakona, about 20 kms away from Silchar. The campus is set amid sprawling hillocks and typical landscape of north east. The campus is spread over 600 acres and provide an ideal environment for the researchers, students and the people interested in academic excellence.

The National Institute of Pharmaceutical Education and Research (NIPER) is the first Institute of its kind to be set up at in the State of Bihar in the year 2007. It is an autonomous institution of national importance, established under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India under NIPER Act 1998 at Hajipur in Vaishali District of Bihar.

National Anti-Doping Agency is an autonomous body of the Ministry of Youth Affairs & Sports, Government of India. NADA is responsible for promoting, coordinating and monitoring the doping control programme in sports in all its forms across the country.

National Anti Doping Agency, India announces Anti-Doping Research Fellowship for 10 PhD Scholars 2023-24

Piramal Group has interests in a portfolio of businesses including financial services (Piramal Enterprises Limited), pharmaceuticals (Piramal Pharma Limited), and real estate (Piramal Realty). With operations in 30 countries and brand presence in over 100 markets, the Group’s turnover is ~1.9 billion usd in FY 2022. Driven by its core values, the Group pursues inclusive growth, while adhering to ethical and value-driven practices.

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Today, Intas is present in more than 85 countries worldwide and is growing at 20% CAGR. Around 70% of its revenues come from the international markets, particularly the highly regulated markets of EU and US. At Intas, every day and everyone works to create a world of good health, happinessand hope.

Finecure Pharmaceuticals Limited and its subsidiaries are leading manufacturers and marketers of Pharmaceutical formulations and Nutraceuticals in several therapeutic segments in dosage forms of Tablets, Capsules, Oral Liquids, Dry Syrup, Powders, Injections and Sachet. Finecure runs on principles of quality management systems as guided by its mission, vision, values and ethics which act as role models. The company is moving towards a long term goal of discovery, development, manufacture, marketing and sales of novel drugs.

Mepro Pharmaceuticals Pvt Ltd., is a privately owned pharmaceutical company with over 5 decades of experience in manufacturing of tablets, capsules, creams/ointments and sterile injectable. Mepro is approved by various regulatory authorities as UK-MHRA, EUGMP, and PIC's nations besides governing bodies of many other countries.

Mepro is looking for ambitious, energetic and dynamic candidates as per the following positions. (EU-GMP APPROVED)

Innoxel Lifesciences Private Limited has it's state-of-the-art advanced manufacturing facility at Kotambi, Vadodara - 391 510, Gujarat, India. In our innovative excellence endeavour for providing high quality life-saving medicine globally (US, EU, Canada and other highly regulated market) we invite competent, passioned and talented individuals to be part of our Innoxel family.

AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.

Cipla South Africa, a 100% owned subsidiary of Cipla Limited signed a binding term sheet with Actor Holdings (Pty) Limited to acquire 100% of the issued ordinary shares of Actor Pharma (Pty) Limited. This development underpins Ciplas commitment and investment in its over the counter (OTC) business and supports its journey to be a leading healthcare player in South Africa. This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market.

Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.

Researchers found that the location in and around tumours of cytotoxic T cells, which play a key role in fighting cancer, may help predict patient survival and indicate whether or not treatments will work.

Scientists from Queen Mary University of London have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to it.

The two genes discovered actively ‘work’ in most human cancer types, meaning the findings could potentially extend to other cancers with elevated levels of the genes.

Gujarat Urban Health Project (Ahmedabad) for Urban Primary Health Center and Urban Community Health Center under Gujarat Urban Health Project for the purpose of making health services equipped, accessible and health infrastructure strong in the metropolitan area of ​​the state with the various resolutions of the Department of Health and Family Welfare of the Government of Gujarat.  By setting up a separate structure named below, the regular posts as mentioned below have been allotted on a 100% grant basis by the Government of Gujarat on a totally village basi